Literature DB >> 11407788

The effect of osteogenic protein-1 on the healing of segmental bone defects treated with autograft or allograft bone.

S L Salkeld1, L P Patron, R L Barrack, S D Cook.   

Abstract

BACKGROUND: Large amounts of bone graft are frequently used to elicit the healing of bone defects resulting from reconstructive procedures. Autograft and allograft bone are often used, but each has its limitations. Bone morphogenetic proteins (BMPs) improve the healing of segmental bone defects treated with autograft or allograft. The objective of the present study was to determine the effect of implantation of a recombinant osteogenic protein-1 (OP-1) in combination with bone graft on the healing of a critical-sized (2.5-cm) segmental defect in canine ulnae.
METHODS: Either autograft bone, allograft bone, osteogenic protein-1 (OP-1) mixed with type-1 bovine collagen, or various combinations of OP-1 and collagen (OP-1 device) mixed with allograft or autograft were implanted in the segmental bone defects. The combinations included 67% bone graft with 33% OP-1 device and 33% bone graft with 67% OP-1 device. The healing of the defects was assessed with radiographic, biomechanical, and histological studies. The animals were killed at twelve weeks postoperatively.
RESULTS: The use of the OP-1 device alone or any combination of autograft or allograft bone and the OP-1 device demonstrated improved healing on radiographic, mechanical, and histological studies compared with that demonstrated after use of autograft or allograft bone alone. The highest radiographic and histological grades and the greatest mechanical strength were achieved with the use of 33% allograft and 67% OP-1 device, although no significant differences were observed among the different groups containing the OP-1 device. At twelve weeks postoperatively, the defects treated with any amount of the OP-1 device obtained greater mechanical strength than that obtained by autograft bone alone.
CONCLUSIONS: Major bone defects may be treated with allograft bone combined with the OP-1 device, instead of autograft alone, to avoid complications associated with the use of autograft. The combination of allograft bone and the OP-1 device resulted in optimum healing of the defect, according to the radiographic, mechanical, and histological parameters measured in this study. CLINICAL RELEVANCE: The combination of freeze-dried allograft bone with the OP-1 device is an attractive graft material for the treatment of large bone defects. Although similar results were observed when autogenous bone graft was used in combination with the OP-1 device, the results of the present study suggest that allograft, because of its relatively unlimited supply, can be substituted without reduced efficacy. In addition, avoiding the need to harvest autogenous bone eliminates the additional operative time and risk associated with a second surgical procedure.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11407788     DOI: 10.2106/00004623-200106000-00001

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  32 in total

1.  Muscle reconstruction in reconstructive surgery: soft tissue repair and long bone reconstruction.

Authors:  A C Masquelet
Journal:  Langenbecks Arch Surg       Date:  2003-09-11       Impact factor: 3.445

2.  Osteogenic protein-1 delivered by hydroxyapatite-coated implants improves bone ingrowth in extracortical bone bridging.

Authors:  Neil Saran; Renwen Zhang; Robert E Turcotte
Journal:  Clin Orthop Relat Res       Date:  2010-09-28       Impact factor: 4.176

3.  Bone morphogenetic protein-2 for the treatment of congenital pseudarthrosis of the tibia or persistent tibial nonunion in children and adolescents: A retrospective study with a minimum 2-year follow-up.

Authors:  Tim N Hissnauer; Norbert Stiel; Kornelia Babin; Martin Rupprecht; Michael Hoffmann; Johannes M Rueger; Ralf Stuecker; Alexander S Spiro
Journal:  J Mater Sci Mater Med       Date:  2017-02-17       Impact factor: 3.896

4.  Histological and immunohistochemical analysis of an allogenic bone graft engineered with autologous bone marrow mononuclear cells in the treatment of a large segmental defect of the ulna. A case report.

Authors:  Sandro Giannini; Francesca Vannini; Gina Lisignoli; Andrea Facchini
Journal:  Chir Organi Mov       Date:  2008-05-21

Review 5.  Controlled release strategies for bone, cartilage, and osteochondral engineering--Part I: recapitulation of native tissue healing and variables for the design of delivery systems.

Authors:  Vítor E Santo; Manuela E Gomes; João F Mano; Rui L Reis
Journal:  Tissue Eng Part B Rev       Date:  2013-02-19       Impact factor: 6.389

6.  Bone union formation in the rat mandibular symphysis using hydroxyapatite with or without simvastatin: effects on healthy, diabetic, and osteoporotic rats.

Authors:  F Camacho-Alonso; C Martínez-Ortiz; L Plazas-Buendía; A M Mercado-Díaz; C Vilaplana-Vivo; J A Navarro; A J Buendía; J J Merino; Y Martínez-Beneyto
Journal:  Clin Oral Investig       Date:  2020-01-11       Impact factor: 3.573

7.  Effect of platelet-rich plasma combined with demineralised bone matrix on bone healing in rabbit ulnar defects.

Authors:  Vasilios Galanis; Alice Fiska; Stylianos Kapetanakis; Konstantinos Kazakos; Thespis Demetriou
Journal:  Singapore Med J       Date:  2016-05-19       Impact factor: 1.858

8.  Demineralized bone matrix and hydroxyapatite/tri-calcium phosphate mixture for bone healing in rats.

Authors:  Ali Oztürk; H Yetkin; L Memis; E Cila; S Bolukbasi; Halil Can Gemalmaz
Journal:  Int Orthop       Date:  2006-03-25       Impact factor: 3.075

9.  Osteogenic protein-1 for long bone nonunion: an evidence-based analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2005-04-01

10.  The synergistic effect of autograft and BMP-7 in the treatment of atrophic nonunions.

Authors:  Peter V Giannoudis; Nikolaos K Kanakaris; Rozalia Dimitriou; Ian Gill; Vinod Kolimarala; Richard J Montgomery
Journal:  Clin Orthop Relat Res       Date:  2009-04-24       Impact factor: 4.176

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.